Eyepoint Pharmaceuticals, Inc. (EYPT)

Trade EYPT now with
5/18/2020 7:10:47 AM EyePoint Presents Data Showcasing DEXYCU At ASCRS 2020 Virtual Annual Meeting
3/5/2020 7:06:08 AM EyePoint Q4 Net Loss $10.4 Mln Or $0.10/Shr
3/2/2020 7:10:58 AM EyePoint Reports Positive Topline 36-month Follow-up Data For Second Phase 3 Study Of YUTIQ
2/21/2020 9:11:29 AM EyePoint Pricies Public Offering Of 15 Mln Shares At $1.45 Per Share
2/18/2020 7:15:33 AM EyePoint, Vision Center Network Of America Sign Purchase Agreement For DEXYCU
1/27/2020 7:10:50 AM EyePoint, Ocumension Enter Exclusive License Agreement For DEXYCU 9%
7/15/2019 7:04:49 AM EyePoint Pharmaceuticals Appoints Wendy DiCicco To Board
6/13/2019 7:08:08 AM EyePoint Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28/2019 9:29:36 AM EyePoint Pharma Announces Pricing Of Underwritten Public Offering Of 10.53 Mln Shares At $1.90/shr
3/14/2019 6:12:17 AM EyePoint Pharma Q2 Net Loss $11.6 Miln Or $0.12/shr Vs Loss Of $5.8 Mln Or $0.13/Shr Last Year
2/4/2019 7:08:43 AM EyePoint Pharmaceuticals Announces U.S. Commercial Launch Of YUTIQ 0.18 Mg In The United States
1/28/2019 7:03:59 AM EyePoint Pharmaceuticals Appoints David Guyer To Board
1/3/2019 7:10:42 AM EyePoint Now Expects DEXYCUTM Commercial Launch In Q1, Earlier Than Prior Guidance Of H1
11/27/2018 4:09:40 PM EyePoint Pharmaceuticals Appoints Ron Honig As SVP, General Counsel & Company Secretary
11/12/2018 7:06:44 AM EyePoint Pharma Announces Assignment Of Permanent J-Code For DEXYCU By Center For Medicare And Medicaid Services
11/6/2018 6:13:43 AM EyePoint Pharma Q1 Net Loss $33.1 Mln Or $0.44/Shr Vs Loss Of $6.0 Mln Or $0.15/Shr Last Year
10/29/2018 7:07:55 AM EyePoint Pharmaceuticals Presents Positive YUTIQ 24-month Follow-up Data At AAO 2018 Annual Meeting
10/18/2018 7:17:41 AM EyePoint Pharma Announces Data Highlighting YUTIQ To Be Presented At AAO 2018 Annual Meeting